Four‐year survival of transfusion recipients identified by hepatitis C lookback

Abstract

When transfusion dose is taken into account, the probability of survival of patients transfused at the New York University Medical Center in 1988 to 1996 and identified by lookback is similar to that reported for Swedish county residents transfused in 1993. Based on both the Swedish data and the information presented here and in the absence of any recent results from population-based studies, the survival of U.S. patients transfused in the 1990s appears to be 20 percent lower than that of Olmsted County residents transfused in 1981.

The epidemiology of transfusion‐associated hepatitis C in a children's hospital

“…This is in contrast to historic HIV and recent HCV lookback in adult recipients where over 65 percent had died before lookback. 22,23 Parents, once contacted, are willing to permit their child's participation and will go to great lengths to obtain testing. Our findings parallel those of Heddle and coworkers 24 who contacted 1546 patients who received transfusions between 1978 and 1985; 30 percent of letters were returned undeliverable but 90 percent of those successfully contacted agreed to testing.…”

Long‐term survival after blood transfusion: a population based study in the North of England

“…Vamvakas and Goldstein 11 have recently reported results of a lookback study at the New York University medical center for patients transfused with blood from HCV‐positive donors between 1988 and 1996. Results from lookback studies at single centers may not always agree with population‐based surveys.…”

Cost-Effectiveness of Alternative Blood-Screening Strategies for West Nile Virus in the United States

“…We utilized unpublished follow-up data on 36 hospitalized patients with WNV to estimate long-term recovery from WNV-associated NI (D. Nash and A. K. Labowitz, personal communication). Distributions of age, sex, and immune status for transfusion recipients were based on transfusion look-back studies [14]. Since there are no population-based studies that reported the probability of developing febrile illness or NI after acquiring transfusion-associated WNV infection, we relied on data from an experimental study of deliberate WNV inoculation of humans with cancer [13].…”